secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001104659-23-113138
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada gets $223.7M upfront from Vertex amendment; $17.5M milestone reached for ENTR-701
--------------------------------------------------------------------------------

- Received $223.7M upfront payment from Vertex under amended collaboration/license agreements.
- Eligible for up to $485M in future research, development, regulatory, and commercial milestones.
- Achieved $17.5M milestone for preclinical IND-enabling GLP toxicology studies of ENTR-701; expected Q4 2023.
- Amendments clarify milestone definitions and payment terms; other terms unchanged.
- Vertex amendments executed Oct 26, 2023; Entrada shares trade on Nasdaq as TRDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923113138/0001104659-23-113138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923113138/tm2329482d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer